Global and United States Antibacterial (Drug) Resistance Market Insights, Forecast to 2026

1 Study Coverage

• 1.1 Antibacterial (Drug) Resistance Product Introduction
• 1.2 Market Segments
• 1.3 Key Antibacterial (Drug) Resistance Manufacturers Covered: Ranking by Revenue
• 1.4 Market by Type
  • 1.4.1 Global Antibacterial (Drug) Resistance Market Size Growth Rate by Type
  • 1.4.2 Telavancin (Vibativ)
  • 1.4.3 Ceftaroline Fosamil (Teflaro/ Zinforo)
  • 1.4.4 Fidaxomicin (Dificid / Dificlir)
  • 1.4.5 Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)
  • 1.4.6 Dalbavancin (Dalvance/ Xydalba)
  • 1.4.7 Tedizolid Phosphate (Sivextro)
  • 1.4.8 Oritavancin (Orbactiv/ Nuvocid)
  • 1.4.9 Ceftolozane-Tazobactam (Zerbaxa)
  • 1.4.10 Ceftazidime-Avibactam (Avycaz/ Zavicefta)
  • 1.4.11 PHASE III DRUGS
• 1.5 Market by Indication
  • 1.5.1 Global Antibacterial (Drug) Resistance Market Size Growth Rate by Indication
  • 1.5.2 Complicated Urinary Tract Infection (CUTI)
  • 1.5.3 Complicated Intra-Abdominal Infections (CIAI)
  • 1.5.4 Blood Stream Infections (BSI)
  • 1.5.5 Clostridium Difficile Infections (CDI)
  • 1.5.6 Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
  • 1.5.7 Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
  • 1.5.8 Community Acquired Bacterial Pneumonia (CABP)
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Antibacterial (Drug) Resistance Market Size, Estimates and Forecasts
  • 2.1.1 Global Antibacterial (Drug) Resistance Revenue 2015-2026
  • 2.1.2 Global Antibacterial (Drug) Resistance Sales 2015-2026
• 2.2 Global Antibacterial (Drug) Resistance, Market Size by Producing Regions: 2015 VS 2020 VS 2026
• 2.3 Antibacterial (Drug) Resistance Historical Market Size by Region (2015-2020)
  • 2.3.1 Global Antibacterial (Drug) Resistance Retrospective Market Scenario in Sales by Region: 2015-2020
  • 2.3.2 Global Antibacterial (Drug) Resistance Retrospective Market Scenario in Revenue by Region: 2015-2020
• 2.4 Antibacterial (Drug) Resistance Market Estimates and Projections by Region (2021-2026)
  • 2.4.1 Global Antibacterial (Drug) Resistance Sales Forecast by Region (2021-2026)
  • 2.4.2 Global Antibacterial (Drug) Resistance Revenue Forecast by Region (2021-2026)

3 Global Antibacterial (Drug) Resistance Competitor Landscape by Players

• 3.1 Global Top Antibacterial (Drug) Resistance Sales by Manufacturers
  • 3.1.1 Global Antibacterial (Drug) Resistance Sales by Manufacturers (2015-2020)
  • 3.1.2 Global Antibacterial (Drug) Resistance Sales Market Share by Manufacturers (2015-2020)
• 3.2 Global Antibacterial (Drug) Resistance Manufacturers by Revenue
  • 3.2.1 Global Antibacterial (Drug) Resistance Revenue by Manufacturers (2015-2020)
  • 3.2.2 Global Antibacterial (Drug) Resistance Revenue Share by Manufacturers (2015-2020)
  • 3.2.3 Global Antibacterial (Drug) Resistance Market Concentration Ratio (CR5 and HHI) (2015-2020)
  • 3.2.4 Global Top 10 and Top 5 Companies by Antibacterial (Drug) Resistance Revenue in 2019
  • 3.2.5 Global Antibacterial (Drug) Resistance Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.3 Global Antibacterial (Drug) Resistance Price by Manufacturers
• 3.4 Global Antibacterial (Drug) Resistance Manufacturing Base Distribution, Product Types
  • 3.4.1 Antibacterial (Drug) Resistance Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Antibacterial (Drug) Resistance Product Type
  • 3.4.3 Date of International Manufacturers Enter into Antibacterial (Drug) Resistance Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

• 4.1 Global Antibacterial (Drug) Resistance Market Size by Type (2015-2020)
  • 4.1.1 Global Antibacterial (Drug) Resistance Sales by Type (2015-2020)
  • 4.1.2 Global Antibacterial (Drug) Resistance Revenue by Type (2015-2020)
  • 4.1.3 Antibacterial (Drug) Resistance Average Selling Price (ASP) by Type (2015-2026)
• 4.2 Global Antibacterial (Drug) Resistance Market Size Forecast by Type (2021-2026)
  • 4.2.1 Global Antibacterial (Drug) Resistance Sales Forecast by Type (2021-2026)
  • 4.2.2 Global Antibacterial (Drug) Resistance Revenue Forecast by Type (2021-2026)
  • 4.2.3 Antibacterial (Drug) Resistance Average Selling Price (ASP) Forecast by Type (2021-2026)
• 4.3 Global Antibacterial (Drug) Resistance Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Indication (2015-2026)

• 5.1 Global Antibacterial (Drug) Resistance Market Size by Indication (2015-2020)
  • 5.1.1 Global Antibacterial (Drug) Resistance Sales by Indication (2015-2020)
  • 5.1.2 Global Antibacterial (Drug) Resistance Revenue by Indication (2015-2020)
  • 5.1.3 Antibacterial (Drug) Resistance Price by Indication (2015-2020)
• 5.2 Antibacterial (Drug) Resistance Market Size Forecast by Indication (2021-2026)
  • 5.2.1 Global Antibacterial (Drug) Resistance Sales Forecast by Indication (2021-2026)
  • 5.2.2 Global Antibacterial (Drug) Resistance Revenue Forecast by Indication (2021-2026)
  • 5.2.3 Global Antibacterial (Drug) Resistance Price Forecast by Indication (2021-2026)

6 United States by Players, Type and Indication

• 6.1 United States Antibacterial (Drug) Resistance Market Size YoY Growth 2015-2026
  • 6.1.1 United States Antibacterial (Drug) Resistance Sales YoY Growth 2015-2026
  • 6.1.2 United States Antibacterial (Drug) Resistance Revenue YoY Growth 2015-2026
  • 6.1.3 United States Antibacterial (Drug) Resistance Market Share in Global Market 2015-2026
• 6.2 United States Antibacterial (Drug) Resistance Market Size by Players (International and Local Players)
  • 6.2.1 United States Top Antibacterial (Drug) Resistance Players by Sales (2015-2020)
  • 6.2.2 United States Top Antibacterial (Drug) Resistance Players by Revenue (2015-2020)
• 6.3 United States Antibacterial (Drug) Resistance Historic Market Review by Type (2015-2020)
  • 6.3.1 United States Antibacterial (Drug) Resistance Sales Market Share by Type (2015-2020)
  • 6.3.2 United States Antibacterial (Drug) Resistance Revenue Market Share by Type (2015-2020)
  • 6.3.3 United States Antibacterial (Drug) Resistance Price by Type (2015-2020)
• 6.4 United States Antibacterial (Drug) Resistance Market Estimates and Forecasts by Type (2021-2026)
  • 6.4.1 United States Antibacterial (Drug) Resistance Sales Forecast by Type (2021-2026)
  • 6.4.2 United States Antibacterial (Drug) Resistance Revenue Forecast by Type (2021-2026)
  • 6.4.3 United States Antibacterial (Drug) Resistance Price Forecast by Type (2021-2026)
• 6.5 United States Antibacterial (Drug) Resistance Historic Market Review by Indication (2015-2020)
  • 6.5.1 United States Antibacterial (Drug) Resistance Sales Market Share by Indication (2015-2020)
  • 6.5.2 United States Antibacterial (Drug) Resistance Revenue Market Share by Indication (2015-2020)
  • 6.5.3 United States Antibacterial (Drug) Resistance Price by Indication (2015-2020)
• 6.6 United States Antibacterial (Drug) Resistance Market Estimates and Forecasts by Indication (2021-2026)
  • 6.6.1 United States Antibacterial (Drug) Resistance Sales Forecast by Indication (2021-2026)
  • 6.6.2 United States Antibacterial (Drug) Resistance Revenue Forecast by Indication (2021-2026)
  • 6.6.3 United States Antibacterial (Drug) Resistance Price Forecast by Indication (2021-2026)

7 North America

• 7.1 North America Antibacterial (Drug) Resistance Market Size YoY Growth 2015-2026
• 7.2 North America Antibacterial (Drug) Resistance Market Facts & Figures by Country
  • 7.2.1 North America Antibacterial (Drug) Resistance Sales by Country (2015-2020)
  • 7.2.2 North America Antibacterial (Drug) Resistance Revenue by Country (2015-2020)
  • 7.2.3 U.S.
  • 7.2.4 Canada

8 Europe

• 8.1 Europe Antibacterial (Drug) Resistance Market Size YoY Growth 2015-2026
• 8.2 Europe Antibacterial (Drug) Resistance Market Facts & Figures by Country
  • 8.2.1 Europe Antibacterial (Drug) Resistance Sales by Country
  • 8.2.2 Europe Antibacterial (Drug) Resistance Revenue by Country
  • 8.2.3 Germany
  • 8.2.4 France
  • 8.2.5 U.K.
  • 8.2.6 Italy
  • 8.2.7 Russia

9 Asia Pacific

• 9.1 Asia Pacific Antibacterial (Drug) Resistance Market Size YoY Growth 2015-2026
• 9.2 Asia Pacific Antibacterial (Drug) Resistance Market Facts & Figures by Country
  • 9.2.1 Asia Pacific Antibacterial (Drug) Resistance Sales by Region (2015-2020)
  • 9.2.2 Asia Pacific Antibacterial (Drug) Resistance Revenue by Region
  • 9.2.3 China
  • 9.2.4 Japan
  • 9.2.5 South Korea
  • 9.2.6 India
  • 9.2.7 Australia
  • 9.2.8 Taiwan
  • 9.2.9 Indonesia
  • 9.2.10 Thailand
  • 9.2.11 Malaysia
  • 9.2.12 Philippines
  • 9.2.13 Vietnam

10 Latin America

• 10.1 Latin America Antibacterial (Drug) Resistance Market Size YoY Growth 2015-2026
• 10.2 Latin America Antibacterial (Drug) Resistance Market Facts & Figures by Country
  • 10.2.1 Latin America Antibacterial (Drug) Resistance Sales by Country
  • 10.2.2 Latin America Antibacterial (Drug) Resistance Revenue by Country
  • 10.2.3 Mexico
  • 10.2.4 Brazil
  • 10.2.5 Argentina

11 Middle East and Africa

• 11.1 Middle East and Africa Antibacterial (Drug) Resistance Market Size YoY Growth 2015-2026
• 11.2 Middle East and Africa Antibacterial (Drug) Resistance Market Facts & Figures by Country
  • 11.2.1 Middle East and Africa Antibacterial (Drug) Resistance Sales by Country
  • 11.2.2 Middle East and Africa Antibacterial (Drug) Resistance Revenue by Country
  • 11.2.3 Turkey
  • 11.2.4 Saudi Arabia
  • 11.2.5 U.A.E

12 Company Profiles

• 12.1 Melinta Therapeutics
  • 12.1.1 Melinta Therapeutics Corporation Information
  • 12.1.2 Melinta Therapeutics Description and Business Overview
  • 12.1.3 Melinta Therapeutics Sales, Revenue and Gross Margin (2015-2020)
  • 12.1.4 Melinta Therapeutics Antibacterial (Drug) Resistance Products Offered
  • 12.1.5 Melinta Therapeutics Recent Development
• 12.2 Allergan
  • 12.2.1 Allergan Corporation Information
  • 12.2.2 Allergan Description and Business Overview
  • 12.2.3 Allergan Sales, Revenue and Gross Margin (2015-2020)
  • 12.2.4 Allergan Antibacterial (Drug) Resistance Products Offered
  • 12.2.5 Allergan Recent Development
• 12.3 Merck
  • 12.3.1 Merck Corporation Information
  • 12.3.2 Merck Description and Business Overview
  • 12.3.3 Merck Sales, Revenue and Gross Margin (2015-2020)
  • 12.3.4 Merck Antibacterial (Drug) Resistance Products Offered
  • 12.3.5 Merck Recent Development
• 12.4 Abbott Laboratories
  • 12.4.1 Abbott Laboratories Corporation Information
  • 12.4.2 Abbott Laboratories Description and Business Overview
  • 12.4.3 Abbott Laboratories Sales, Revenue and Gross Margin (2015-2020)
  • 12.4.4 Abbott Laboratories Antibacterial (Drug) Resistance Products Offered
  • 12.4.5 Abbott Laboratories Recent Development
• 12.5 Pfizer
  • 12.5.1 Pfizer Corporation Information
  • 12.5.2 Pfizer Description and Business Overview
  • 12.5.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
  • 12.5.4 Pfizer Antibacterial (Drug) Resistance Products Offered
  • 12.5.5 Pfizer Recent Development
• 12.6 GSK
  • 12.6.1 GSK Corporation Information
  • 12.6.2 GSK Description and Business Overview
  • 12.6.3 GSK Sales, Revenue and Gross Margin (2015-2020)
  • 12.6.4 GSK Antibacterial (Drug) Resistance Products Offered
  • 12.6.5 GSK Recent Development
• 12.7 PENDOPHARM
  • 12.7.1 PENDOPHARM Corporation Information
  • 12.7.2 PENDOPHARM Description and Business Overview
  • 12.7.3 PENDOPHARM Sales, Revenue and Gross Margin (2015-2020)
  • 12.7.4 PENDOPHARM Antibacterial (Drug) Resistance Products Offered
  • 12.7.5 PENDOPHARM Recent Development
• 12.8 Absynth Biologics
  • 12.8.1 Absynth Biologics Corporation Information
  • 12.8.2 Absynth Biologics Description and Business Overview
  • 12.8.3 Absynth Biologics Sales, Revenue and Gross Margin (2015-2020)
  • 12.8.4 Absynth Biologics Antibacterial (Drug) Resistance Products Offered
  • 12.8.5 Absynth Biologics Recent Development
• 12.9 Achaogen
  • 12.9.1 Achaogen Corporation Information
  • 12.9.2 Achaogen Description and Business Overview
  • 12.9.3 Achaogen Sales, Revenue and Gross Margin (2015-2020)
  • 12.9.4 Achaogen Antibacterial (Drug) Resistance Products Offered
  • 12.9.5 Achaogen Recent Development
• 12.10 Acino Holdings
  • 12.10.1 Acino Holdings Corporation Information
  • 12.10.2 Acino Holdings Description and Business Overview
  • 12.10.3 Acino Holdings Sales, Revenue and Gross Margin (2015-2020)
  • 12.10.4 Acino Holdings Antibacterial (Drug) Resistance Products Offered
  • 12.10.5 Acino Holdings Recent Development
• 12.11 Melinta Therapeutics
  • 12.11.1 Melinta Therapeutics Corporation Information
  • 12.11.2 Melinta Therapeutics Description and Business Overview
  • 12.11.3 Melinta Therapeutics Sales, Revenue and Gross Margin (2015-2020)
  • 12.11.4 Melinta Therapeutics Antibacterial (Drug) Resistance Products Offered
  • 12.11.5 Melinta Therapeutics Recent Development
• 12.12 Austell Laboratories
  • 12.12.1 Austell Laboratories Corporation Information
  • 12.12.2 Austell Laboratories Description and Business Overview
  • 12.12.3 Austell Laboratories Sales, Revenue and Gross Margin (2015-2020)
  • 12.12.4 Austell Laboratories Products Offered
  • 12.12.5 Austell Laboratories Recent Development
• 12.13 Assembly Biosciences
  • 12.13.1 Assembly Biosciences Corporation Information
  • 12.13.2 Assembly Biosciences Description and Business Overview
  • 12.13.3 Assembly Biosciences Sales, Revenue and Gross Margin (2015-2020)
  • 12.13.4 Assembly Biosciences Products Offered
  • 12.13.5 Assembly Biosciences Recent Development
• 12.14 Arpida
  • 12.14.1 Arpida Corporation Information
  • 12.14.2 Arpida Description and Business Overview
  • 12.14.3 Arpida Sales, Revenue and Gross Margin (2015-2020)
  • 12.14.4 Arpida Products Offered
  • 12.14.5 Arpida Recent Development
• 12.15 Demuris
  • 12.15.1 Demuris Corporation Information
  • 12.15.2 Demuris Description and Business Overview
  • 12.15.3 Demuris Sales, Revenue and Gross Margin (2015-2020)
  • 12.15.4 Demuris Products Offered
  • 12.15.5 Demuris Recent Development
• 12.16 Evolva Holding
  • 12.16.1 Evolva Holding Corporation Information
  • 12.16.2 Evolva Holding Description and Business Overview
  • 12.16.3 Evolva Holding Sales, Revenue and Gross Margin (2015-2020)
  • 12.16.4 Evolva Holding Products Offered
  • 12.16.5 Evolva Holding Recent Development
• 12.17 ContraFect
  • 12.17.1 ContraFect Corporation Information
  • 12.17.2 ContraFect Description and Business Overview
  • 12.17.3 ContraFect Sales, Revenue and Gross Margin (2015-2020)
  • 12.17.4 ContraFect Products Offered
  • 12.17.5 ContraFect Recent Development
• 12.18 Cerexa
  • 12.18.1 Cerexa Corporation Information
  • 12.18.2 Cerexa Description and Business Overview
  • 12.18.3 Cerexa Sales, Revenue and Gross Margin (2015-2020)
  • 12.18.4 Cerexa Products Offered
  • 12.18.5 Cerexa Recent Development
• 12.19 InterMune
  • 12.19.1 InterMune Corporation Information
  • 12.19.2 InterMune Description and Business Overview
  • 12.19.3 InterMune Sales, Revenue and Gross Margin (2015-2020)
  • 12.19.4 InterMune Products Offered
  • 12.19.5 InterMune Recent Development
• 12.20 Isis Pharmaceuticals
  • 12.20.1 Isis Pharmaceuticals Corporation Information
  • 12.20.2 Isis Pharmaceuticals Description and Business Overview
  • 12.20.3 Isis Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
  • 12.20.4 Isis Pharmaceuticals Products Offered
  • 12.20.5 Isis Pharmaceuticals Recent Development
• 12.21 Lyndra
  • 12.21.1 Lyndra Corporation Information
  • 12.21.2 Lyndra Description and Business Overview
  • 12.21.3 Lyndra Sales, Revenue and Gross Margin (2015-2020)
  • 12.21.4 Lyndra Products Offered
  • 12.21.5 Lyndra Recent Development
• 12.22 Microbecide
  • 12.22.1 Microbecide Corporation Information
  • 12.22.2 Microbecide Description and Business Overview
  • 12.22.3 Microbecide Sales, Revenue and Gross Margin (2015-2020)
  • 12.22.4 Microbecide Products Offered
  • 12.22.5 Microbecide Recent Development
• 12.23 Morphochem
  • 12.23.1 Morphochem Corporation Information
  • 12.23.2 Morphochem Description and Business Overview
  • 12.23.3 Morphochem Sales, Revenue and Gross Margin (2015-2020)
  • 12.23.4 Morphochem Products Offered
  • 12.23.5 Morphochem Recent Development
• 12.24 Nabriva Therapeutics
  • 12.24.1 Nabriva Therapeutics Corporation Information
  • 12.24.2 Nabriva Therapeutics Description and Business Overview
  • 12.24.3 Nabriva Therapeutics Sales, Revenue and Gross Margin (2015-2020)
  • 12.24.4 Nabriva Therapeutics Products Offered
  • 12.24.5 Nabriva Therapeutics Recent Development
• 12.25 NanoSafe Coatings
  • 12.25.1 NanoSafe Coatings Corporation Information
  • 12.25.2 NanoSafe Coatings Description and Business Overview
  • 12.25.3 NanoSafe Coatings Sales, Revenue and Gross Margin (2015-2020)
  • 12.25.4 NanoSafe Coatings Products Offered
  • 12.25.5 NanoSafe Coatings Recent Development
• 12.26 Novexel
  • 12.26.1 Novexel Corporation Information
  • 12.26.2 Novexel Description and Business Overview
  • 12.26.3 Novexel Sales, Revenue and Gross Margin (2015-2020)
  • 12.26.4 Novexel Products Offered
  • 12.26.5 Novexel Recent Development
• 12.27 Osel
  • 12.27.1 Osel Corporation Information
  • 12.27.2 Osel Description and Business Overview
  • 12.27.3 Osel Sales, Revenue and Gross Margin (2015-2020)
  • 12.27.4 Osel Products Offered
  • 12.27.5 Osel Recent Development
• 12.28 VenatoRx Pharmaceuticals
  • 12.28.1 VenatoRx Pharmaceuticals Corporation Information
  • 12.28.2 VenatoRx Pharmaceuticals Description and Business Overview
  • 12.28.3 VenatoRx Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
  • 12.28.4 VenatoRx Pharmaceuticals Products Offered
  • 12.28.5 VenatoRx Pharmaceuticals Recent Development
• 12.29 AAIPharma Services
  • 12.29.1 AAIPharma Services Corporation Information
  • 12.29.2 AAIPharma Services Description and Business Overview
  • 12.29.3 AAIPharma Services Sales, Revenue and Gross Margin (2015-2020)
  • 12.29.4 AAIPharma Services Products Offered
  • 12.29.5 AAIPharma Services Recent Development
• 12.30 ANTABIO
  • 12.30.1 ANTABIO Corporation Information
  • 12.30.2 ANTABIO Description and Business Overview
  • 12.30.3 ANTABIO Sales, Revenue and Gross Margin (2015-2020)
  • 12.30.4 ANTABIO Products Offered
  • 12.30.5 ANTABIO Recent Development

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Porter’s Five Forces Analysis
• 13.5 Primary Interviews with Key Antibacterial (Drug) Resistance Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Antibacterial (Drug) Resistance Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details